THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Life Sciences: Biotech

Start-ups turning to hedge funds

Shift is challenge to venture capital

By Stephen Heuser
Globe Staff / May 29, 2006

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

When the private biotechnology company Microbia Inc. closed a $75 million round of funding in February, investors sat up and took notice. Not only because the Cambridge firm had just landed the biggest local round of biotechnology venture financing in two years, but also because a large chunk of the money came from hedge funds. (Full article: 1044 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass